Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HP-3020 (palonosetron)
- Development stage
- Unknown
- Lead developer
- Hisamitsu Pharmaceutical
- Modality
- Small Molecules
- Administration
- Transdermal
01
Overview
HP-3020 is a transdermal patch formulation of **palonosetron**, a second-generation 5-HT3 (serotonin type 3) receptor antagonist, developed by **Hisamitsu Pharmaceutical**. It is designed for the prevention of **chemotherapy-induced nausea and vomiting (CINV)**. Unlike the standard intravenous or oral formulations (such as Aloxi), HP-3020 utilizes Hisamitsu's proprietary transdermal drug delivery system to provide sustained release of palonosetron over 24-hour or 168-hour (7-day) application periods. This non-invasive modality aims to improve patient compliance and provide long-lasting antiemetic coverage, particularly for delayed CINV. Clinical development has focused on pharmacokinetic comparisons with intravenous palonosetron to establish bioequivalence and safety in healthy volunteers.
- Other names
- palonosetron transdermal patch
02
Targets
HTR3A (5-hydroxytryptamine receptor 3A)
Beyond the preview
Go deeper on HP-3020 (palonosetron).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HP-3020 (palonosetron).